Real-World Tumor Response of Palbociclib Plus Letrozole Versus Letrozole for Metastatic Breast Cancer in US Clinical Practice
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Real-World Tumor Response of Palbociclib Plus Letrozole Versus Letrozole for Metastatic Breast Cancer in US Clinical Practice
Authors
Keywords
-
Journal
Targeted Oncology
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-08-10
DOI
10.1007/s11523-021-00826-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- CDK4/6 inhibitors in HR+/HER2- advanced/metastatic breast cancer: a systematic literature review of real-world evidence studies
- (2021) Nadia Harbeck et al. Future Oncology
- Concordance of real-world versus conventional progression-free survival from a phase 3 trial of endocrine therapy as first-line treatment for metastatic breast cancer
- (2020) Cynthia Huang Bartlett et al. PLoS One
- Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up
- (2019) H. S. Rugo et al. BREAST CANCER RESEARCH AND TREATMENT
- Retrospective Analysis of Treatment Patterns and Effectiveness of Palbociclib and Subsequent Regimens in Metastatic Breast Cancer
- (2019) Jing Xi et al. Journal of the National Comprehensive Cancer Network
- Real-world clinical outcomes and toxicity in metastatic breast cancer patients treated with palbociclib and endocrine therapy
- (2019) Leticia Varella et al. BREAST CANCER RESEARCH AND TREATMENT
- Generalisability of Common Oncology Clinical Trial Eligibility Criteria in the Real World
- (2019) S. Karim et al. CLINICAL ONCOLOGY
- Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non–Small Cell Lung Cancer Using a Clinicogenomic Database
- (2019) Gaurav Singal et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- 327PPalbociclib plus an aromatase inhibitor as first-line therapy for metastatic breast cancer in US clinical practices: Real-world progression-free survival analysis
- (2019) M Torres et al. ANNALS OF ONCOLOGY
- Role of real-world evidence in informing cancer care: lessons from colorectal cancer
- (2019) A. Batra et al. Current Oncology
- Development and Validation of a High-Quality Composite Real-World Mortality Endpoint
- (2018) Melissa D. Curtis et al. HEALTH SERVICES RESEARCH
- Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor‐positive, advanced breast cancer: A real‐world experience
- (2018) Laura Pizzuti et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Treatment patterns and clinical outcomes among patients receiving palbociclib in combination with an aromatase inhibitor or fulvestrant for HR+/HER2-negative advanced/metastatic breast cancer in real-world settings in the US: Results from the IRIS study
- (2018) Gavin Taylor-Stokes et al. BREAST
- MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
- (2017) Matthew P. Goetz et al. JOURNAL OF CLINICAL ONCOLOGY
- Palbociclib and Letrozole in Advanced Breast Cancer
- (2016) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
- (2015) Richard S Finn et al. LANCET ONCOLOGY
- The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments
- (2013) Peter C. Austin STATISTICS IN MEDICINE
- Assessing Tumor Response to Therapy
- (2009) W. A. Weber JOURNAL OF NUCLEAR MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started